Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load

Abstract This study was a meta-analysis of the literature on the efficacy and safety of tenofovir disoproxil fumarate (TDF) in preventing vertical transmission of hepatitis B in pregnancies with high viral load. Four observational studies and one randomized controlled trial involving 585 pregnant wo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jun-Ze Chen, Zuo-Wei Liao, Fei-Long Huang, Ru-Kui Su, Wen-Bo Wang, Xue-Yuan Cheng, Jie-Qing Chen, Jia-Qi Liu, Zhong Huang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e02740ebd91c427691416f000857ae0a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e02740ebd91c427691416f000857ae0a
record_format	dspace
spelling	oai:doaj.org-article:e02740ebd91c427691416f000857ae0a2021-12-02T15:05:42ZEfficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load10.1038/s41598-017-04479-x2045-2322https://doaj.org/article/e02740ebd91c427691416f000857ae0a2017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-04479-xhttps://doaj.org/toc/2045-2322Abstract This study was a meta-analysis of the literature on the efficacy and safety of tenofovir disoproxil fumarate (TDF) in preventing vertical transmission of hepatitis B in pregnancies with high viral load. Four observational studies and one randomized controlled trial involving 585 pregnant women and 595 newborns were included in the meta-analysis. TDF was more effective than the placebo in reducing vertical transmission in HBeAg-positive chronic hepatitis B (CHB) pregnancies with high serum HBV-DNA levels (OR = 0.21, 95% CI = 0.07–0.61) at 4–12 months, infant HBV DNA seropositivity at delivery (OR = 0.16, 95% CI = 0.07–0.37), and a severe flair in maternal alanine aminotransferase (ALT) levels (OR = 0.43, 95% CI = 0.19–0.95) during pregnancy. In addition, TDF showed more improvement in HBV DNA suppression at delivery (OR = 254.46, 95% CI = 28.39–2280.79). No significant differences were found in HBeAg seroconversion or ALT normalization; or in rates of cesarean section, emergent cesarean section, postpartum hemorrhage, prematurity, congenital malformations, or infant death. However, TDF induced more drug-related adverse events (OR = 2.33, 95% CI = 1.39–3.89) and elevated creatine kinase (CK) (OR = 9.56, 95% CI = 1.17–78.09) than in controls. The available evidence suggests that TDF is effective and safe in preventing vertical transmission of hepatitis B in pregnancies exhibiting a high viral load.Jun-Ze ChenZuo-Wei LiaoFei-Long HuangRu-Kui SuWen-Bo WangXue-Yuan ChengJie-Qing ChenJia-Qi LiuZhong HuangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jun-Ze Chen Zuo-Wei Liao Fei-Long Huang Ru-Kui Su Wen-Bo Wang Xue-Yuan Cheng Jie-Qing Chen Jia-Qi Liu Zhong Huang Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load
description	Abstract This study was a meta-analysis of the literature on the efficacy and safety of tenofovir disoproxil fumarate (TDF) in preventing vertical transmission of hepatitis B in pregnancies with high viral load. Four observational studies and one randomized controlled trial involving 585 pregnant women and 595 newborns were included in the meta-analysis. TDF was more effective than the placebo in reducing vertical transmission in HBeAg-positive chronic hepatitis B (CHB) pregnancies with high serum HBV-DNA levels (OR = 0.21, 95% CI = 0.07–0.61) at 4–12 months, infant HBV DNA seropositivity at delivery (OR = 0.16, 95% CI = 0.07–0.37), and a severe flair in maternal alanine aminotransferase (ALT) levels (OR = 0.43, 95% CI = 0.19–0.95) during pregnancy. In addition, TDF showed more improvement in HBV DNA suppression at delivery (OR = 254.46, 95% CI = 28.39–2280.79). No significant differences were found in HBeAg seroconversion or ALT normalization; or in rates of cesarean section, emergent cesarean section, postpartum hemorrhage, prematurity, congenital malformations, or infant death. However, TDF induced more drug-related adverse events (OR = 2.33, 95% CI = 1.39–3.89) and elevated creatine kinase (CK) (OR = 9.56, 95% CI = 1.17–78.09) than in controls. The available evidence suggests that TDF is effective and safe in preventing vertical transmission of hepatitis B in pregnancies exhibiting a high viral load.
format	article
author	Jun-Ze Chen Zuo-Wei Liao Fei-Long Huang Ru-Kui Su Wen-Bo Wang Xue-Yuan Cheng Jie-Qing Chen Jia-Qi Liu Zhong Huang
author_facet	Jun-Ze Chen Zuo-Wei Liao Fei-Long Huang Ru-Kui Su Wen-Bo Wang Xue-Yuan Cheng Jie-Qing Chen Jia-Qi Liu Zhong Huang
author_sort	Jun-Ze Chen
title	Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load
title_short	Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load
title_full	Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load
title_fullStr	Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load
title_full_unstemmed	Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load
title_sort	efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis b in pregnancies with high viral load
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/e02740ebd91c427691416f000857ae0a
work_keys_str_mv	AT junzechen efficacyandsafetyoftenofovirdisoproxilfumarateinpreventingverticaltransmissionofhepatitisbinpregnancieswithhighviralload AT zuoweiliao efficacyandsafetyoftenofovirdisoproxilfumarateinpreventingverticaltransmissionofhepatitisbinpregnancieswithhighviralload AT feilonghuang efficacyandsafetyoftenofovirdisoproxilfumarateinpreventingverticaltransmissionofhepatitisbinpregnancieswithhighviralload AT rukuisu efficacyandsafetyoftenofovirdisoproxilfumarateinpreventingverticaltransmissionofhepatitisbinpregnancieswithhighviralload AT wenbowang efficacyandsafetyoftenofovirdisoproxilfumarateinpreventingverticaltransmissionofhepatitisbinpregnancieswithhighviralload AT xueyuancheng efficacyandsafetyoftenofovirdisoproxilfumarateinpreventingverticaltransmissionofhepatitisbinpregnancieswithhighviralload AT jieqingchen efficacyandsafetyoftenofovirdisoproxilfumarateinpreventingverticaltransmissionofhepatitisbinpregnancieswithhighviralload AT jiaqiliu efficacyandsafetyoftenofovirdisoproxilfumarateinpreventingverticaltransmissionofhepatitisbinpregnancieswithhighviralload AT zhonghuang efficacyandsafetyoftenofovirdisoproxilfumarateinpreventingverticaltransmissionofhepatitisbinpregnancieswithhighviralload
_version_	1718388738240806912

Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load

Ejemplares similares